Noel P. Bouck

TL;DR: Transfection assays indicate that, in fibroblasts, wild-type p53 inhibits angiogenesis through regulation of TSP-1 synthesis.

TL;DR: The results suggest that PEDF may be of therapeutic use, especially in retinopathies where pathological neovascularization compromises vision and leads to blindness.

TL;DR: A secreted inhibitor of angiogenesis that is controlled by a tumor suppressor gene in hamster cells has been found to be similar to a fragment of the platelet and matrix protein thrombospondin, which demonstrates a function for the ubiquitous adhesive glycoprotein thromBosponin that is likely to be important in the normal physiological down-regulation of neovascularization.

TL;DR: It is shown that thrombospondin-1 is responsible for a significant proportion of the activation of TGF-beta1 in vivo, and lung and pancreatic abnormalities reverted toward wild type when pups were treated with a peptide derived from thromBospondIn1 that could activate T GF- beta1.

TL;DR: Results indicate that thrombospondin-1, and possibly other broad-spectrum natural inhibitors of angiogenesis, act in vivo by inducing receptor-mediated apoptosis in activated microvascular endothelial cells.